CD33, also referred to as Siglec-3, is a transmembrane receptor expressed on cells of myeloid lineage that is expressed in more than 90% of patients with acute myeloid leukemia (AML).49 Therefore, it may be a potential target for the treatment of AML. Here, CD33 is linked to acute myeloid leukemia.